Our study assessed LFTs for both lower and peak levels, identifying a statistically significant elevation in total bilirubin and ALT among COVID-19 patients, which is consistent with previous findings.16 Ultrasound examinations most commonly identified hepatobiliary abnormalities, with 62 of 158 patients displaying diffuse liver hyperechogenicity and 20 of 158 showing an enlarged liver with diffuse hyperechogenicity. The gene discussed is GPT; the disease is COVID-19.